Northpond Ventures

Founded 2018
Founders Michael Rubin Sharon Kedar

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 54
Average round size
info
The average size of a deal this fund participated in
$32M
Portfolio companies 43
Rounds per year 18.00
Lead investments 11
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.31
Exits 2
Key employees 3
Stages of investment
Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Health Diagnostics
  • Medical
  • Life Science
Summary

In 2018 was created Northpond Ventures, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Bethesda.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Northpond Ventures, startups are often financed by ARCH Venture Partners, Sands Capital Ventures, Connecticut Innovations. The meaningful sponsors for the fund in investment in the same round are Sands Capital Ventures, Think.Health, Spring Mountain Capital. In the next rounds fund is usually obtained by National Cancer Institute SBIR Development Center, Think.Health, Spring Mountain Capital.

The real fund results show that this VC is 64 percentage points more often commits exit comparing to other companies. The fund is generally included in 13-24 deals every year. The top activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund.

The current fund was established by Michael Rubin, Sharon Kedar. Besides them, we counted 3 critical employees of this fund in our database.

Among the various public portfolio startups of the fund, we may underline Ultivue, 908 Devices, Candel Besides, a startup needs to be aged 6-10 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical, Software. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the location of its establishment and the land of its numerous investments - United States.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Emulate

Biotechnology
Commercial
Health Care
Life Science
Medical
$82M07 Sep 2021 Boston, Massachusetts, United States

Sound Agriculture

Agriculture
Biotechnology
Farming
$45M19 Aug 2021 California, United States

Vigil Neuroscience

Biotechnology
$90M18 Aug 2021 Cambridge, Massachusetts, United States

Slingshot Biosciences

Biotechnology
Medical
Therapeutics
$23M22 Jul 2021 Emeryville, California, United States

CAMP4 Therapeutics

Biopharma
Biotechnology
Therapeutics
$45M15 Jun 2021 Cambridge, Massachusetts, United States

Hawthorne Effect

Clinical Trials
Health Care
Information Technology
$20M09 Jun 2021 California, United States

Torus Biosystems

Biotechnology
Medical
Test and Measurement
$25M26 May 2021 Cambridge, Massachusetts, United States

Isolere Bio

Biotechnology
Health Care
Therapeutics
$7M05 May 2021 Durham, North Carolina, United States

Outcomes4Me

Health Care
Information Technology
Medical
Personal Health
Software
$12M28 Apr 2021 Cambridge, Massachusetts, United States
News
SimBioSys Raises $15 Million Series A to Develop the Future of Precision Cancer Care

– SimBioSys announced it raised $15m in Series A funding to accelerate the development and commercialization of its TumorScope software platform.
– The company’s novel, simulation-based, precision medicine platform enables individualized treatment planning for cancer patients.
– This Series A was co-led by Genoa Ventures and Northpond Ventures, with participation from AV8 Ventures, Heritage Medical Group, and Mayo Clinic.
– Existing investors and founders also participated in this financing round, bringing the company’s total capital raised to $21m.
– In the first half of 2021, SimBioSys tripled its headcount, bringing in expert clinicians, scientists, and executives from the life sciences industry.

Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama

– Saama technologies announced a strategic growth investment and will be acquired by Carlyle.
– Saama’s intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
– As an end-to-end platform, LSAC provides a unified approach to clinical trial data management and analytics.
– Carlyle has made a strategic growth investment and will acquire a majority stake in the Company.
– A broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners, will be investing alongside Carlyle.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Northpond Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: